▲ Peaking
Business
‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
Cancer vaccine shows promising results, contradicting dire predictions.
Merck
30 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Merck
This hub groups 30 separate news trends connected to Merck, spanning June 30, 2026 through October 27, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 252 article observations and 231 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
▲ Peaking
Business
🔮 fades ✓
First personalised cancer vaccine cuts risk of disease returning in major trial
10 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media
Moderna shares plunged after positive melanoma cancer-vaccine trial data leaked on social media, threatening the drugmaker's record August rally.
◼ Archived
Business
🔮 fades ✓
What to expect from the Moderna-Merck cancer vaccine data reveal
Moderna-Merck cancer vaccine data reveal promising results for high-risk melanoma patients.
◼ Archived
Business
🔮 fades ✓
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Merck's cancer vaccine production timeline is expected to shorten.
◼ Archived
Business
🔮 fades ✓
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte's stock soars 36% as pneumococcal vaccine shows promise against Pfizer and Merck.
◼ Archived
Health
🔮 fades ✓
Exclusive | She was ready to die. Now she’s in remission
A woman's remarkable recovery from cancer raises hopes for new vaccines.
◼ Archived
Business
🔮 fades ✓
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck pays $400 million up front to lock worldwide rights to a KRAS G12D inhibitor in a deal that could swell to over $2 billion.
◼ Archived
Business
🔮 fades ✓
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
A $4 billion Merck‑Daiichi lung‑cancer partnership falters as the firms pull their FDA filing.
◼ Archived
Business
🔮 fades ✓
Merck sees pivotal victory for $3B eye disease prospect
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck's mRNA cancer vaccine win marks a new treatment era.
◼ Archived
Business
🔮 fades ✓
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines spark a biotech gold rush, drawing investors and reshaping oncology treatment.
◼ Archived
Business
🔮 fades ✓
Summit Packs A Punch For Merck's Keytruda
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink
Moderna's cancer vaccine trials could transform treatment, but the math is still out.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
◼ Archived
Health
🔮 fades ✓
Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks
The Democratic Republic of the Congo is receiving a large shipment of Ebola vaccines, but the strain of the virus is unknown.
◼ Archived
Business
🔮 fades ✓
Why Is Moderna Stock Down Today?
Moderna's stock is down despite promising news about a cancer vaccine.
◼ Archived
Business
🔮 fades ✓
After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
Moderna's stock surge on a cancer drug breakthrough has Wall Street abuzz with speculation about the future of cancer treatment.
◼ Archived
Business
Wall St recovers as yields ease; Moderna lifts healthcare stocks
Investors see broad gains across stocks, bonds, gold, and bitcoin as a new Treasury buyback plan shifts market sentiment.
◼ Archived
Business
🔮 fades ✓
Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna's shares have doubled since August 19th, 2026, as investors react to a breakthrough in cancer treatment.
◼ Archived
Business
🔮 fades ✓
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
◼ Archived
Business
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna's stock surges as a melanoma vaccine developed with Merck shows promise in a large trial
◼ Archived
Business
🔮 fades ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial
◼ Archived
Health
Drugmakers uninterested in Trump’s order to split up MMR vaccine
Drugmakers are resisting a Trump-era order to split the MMR vaccine, despite the potential for increased revenue.
◼ Archived
Business
🔮 fades ✓
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline
Merck's mixed financial outlook for 2026 is drawing attention as acquisition costs and new drug sales create opposing trends.
◼ Archived
Business
🔮 fades ✓
With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access
Merck is taking steps to ensure global access to its experimental monthly HIV prevention pill.
◼ Archived
Business
🔮 fades ✓
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
Prediction platform Kalshi is launching sports-style betting markets focused on biotech clinical trials and FDA drug approvals.
◼ Archived
Business
🔮 holds ✓
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved a first-of-its-kind cholesterol pill from Merck designed to drive cholesterol levels lower than statins.
◼ Archived
Business
🔮 fades ✓
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A US House committee has launched an investigation into Merck and AbbVie regarding drug trials conducted in China.